The Precision Peptide Genetic Test does not predict response to retatrutide or any compound
Its role in the future of obesity management is still unfolding, and continued research will further clarify its long-term effects and optimal use in weight management strategies.
The FDA's April 30, 2026 proposal to exclude semaglutide from the 503B bulk substances list - currently in public comment through June 29, 2026 - would, if finalized, close large-scale outsourcing-facility compounding of semaglutide from bulk entirely
Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes, Diabetes Research and Clinical Practice, 238 , (113404), (2026)
IGF-1 signaling is frequently evaluated in relation to muscle metabolism, tissue turnover, recovery signaling, and body composition research